glp-1 drugs in development Discovery of GLP-1–Based for the Treatment of Obesity Emerging Trends in the Development
Description
Side effects and tolerability: Nausea, vomiting, or digestive issues sometimes lead patients to stop treatment
Zepbound will be added to Cigna $CI Healthcares commercial formularies beginning Dec
10.2337/diabetes.52.1.124
, through actions on DPP-4 substrates and adipokines [99]
two in the control group, without any significant difference between the groups (6.8% vs
ACS Omega
